MRE-269
Modify Date: 2025-08-20 10:10:18
MRE-269 structure
|
Common Name | MRE-269 | ||
|---|---|---|---|---|
| CAS Number | 475085-57-5 | Molecular Weight | 419.516 | |
| Density | 1.2±0.1 g/cm3 | Boiling Point | 602.1±55.0 °C at 760 mmHg | |
| Molecular Formula | C25H29N3O3 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 318.0±31.5 °C | |
Use of MRE-269MRE-269 is an active metabolite of selexipag, and acts as a selective IP receptor agonist. |
| Name | {4-[(5,6-Diphenyl-2-pyrazinyl)(isopropyl)amino]butoxy}acetic acid |
|---|---|
| Synonym | More Synonyms |
| Description | MRE-269 is an active metabolite of selexipag, and acts as a selective IP receptor agonist. |
|---|---|
| Related Catalog | |
| Target |
IP Receptor |
| In Vitro | MRE-269 induces endothelium-independent vasodilation of rat extralobar pulmonary artery (EPA). MRE-269 or other IP receptor agonists including epoprostenol, iloprost, treprostinil and beraprost increase cAMP levels in hPASMC[1]. MRE-269 induces concentration-dependent vasodilation in LPA(+), LPA(-), and SPA(-)[3]. |
| In Vivo | The vasorelaxant effects of MRE-269 on rat small intralobar pulmonary artery (SIPA) and EPA are the same, while the other IP receptor agonists induce less vasodilation in SIPA than in EPA[1]. MRE-269 produces substantial relaxation of rat small pulmonary artery, although its effects are only significant at high concentrations of above 10 μM (pEC50, 4.98±0.22). By contrast, in rat small pulmonary veins, MRE-269 only produces minimal relaxation over the whole concentration range, with only significant relaxation occurring at the two highest doses of MRE-269 of 10 and 100 μM[2]. |
| References |
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 602.1±55.0 °C at 760 mmHg |
| Molecular Formula | C25H29N3O3 |
| Molecular Weight | 419.516 |
| Flash Point | 318.0±31.5 °C |
| Exact Mass | 419.220886 |
| PSA | 75.55000 |
| LogP | 5.09 |
| Vapour Pressure | 0.0±1.8 mmHg at 25°C |
| Index of Refraction | 1.588 |
| Storage condition | 2-8℃ |
![2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}acetic acid tert-butyl ester structure](https://image.chemsrc.com/caspic/404/475084-96-9.png)
| Precursor 1 | |
|---|---|
| DownStream 0 | |
| Acetic acid, 2-[4-[(5,6-diphenyl-2-pyrazinyl)(1-methylethyl)amino]butoxy]- |
| MRE-269 |
| 2-[4-({[(3,5-DICHLOROPHENYL)AMINO]CARBONYL}AMINO)PHENOXY]-2-METHYLPROPANOIC ACID |
| 2-(4-{[(3,5-dichlorophenyl)carbamoyl]amino}phenoxy)-2-methylpropanoic acid |
| {4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}acetic acid |
| {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid |
| 4-(3,5-dichlorophenylureido)phenoxyisobutyric acid |
| {4-[(5,6-Diphenyl-2-pyrazinyl)(isopropyl)amino]butoxy}acetic acid |
| ACT-333679 |
| 2-<4<<<(3,5-dichlorophenyl)amino>carbonyl>amino>phenoxy>-2-methylpropionic acid |
| 2-{4-[N'-(3,5-dichlorophenyl)ureido]phenoxy}isobutyric acid |
| 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}acetic acid |
| Propanoic acid,2-[4-[[[(3,5-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl |